.Attributes Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a median consequence of 11 months, people along with metastatic gastrointestinal lumps who received biomarker-matched therapies based on flowing growth DNA profiling presented a greater professional advantage than those receiving unequaled treatment.